Remi Gaston-Dreyfus - 15 Jul 2021 Form 4 Insider Report for Bionik Laboratories Corp.

Role
Director, 10%+ Owner
Signature
/s/ Remi Gaston-Dreyfus
Issuer symbol
BNKL on OTC
Transactions as of
15 Jul 2021
Net transactions value
$0
Form type
4
Filing time
13 Dec 2021, 15:32:03 UTC
Previous filing
13 Dec 2021
Next filing
21 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BNKL Common Stock, par value $0.001 per share Options Exercise +115,759 +7.8% 1,595,209 15 Jul 2021 Shares held through RGD Investissements S.A.S. and Lombard International Assurance SA F1
transaction BNKL Common Stock, par value $0.001 per share Options Exercise +5,000 +0.31% 1,600,209 15 Jul 2021 Shares held through RGD Investissements S.A.S. and Lombard International Assurance SA F1
holding BNKL Common Stock, par value $0.001 per share 61,256 15 Jul 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BNKL Stock Option (right to buy) Options Exercise $0 -115,759 -100% $0.000000* 0 15 Jul 2021 Common Stock, par value $0.001 per share 115,759 $3.60 Direct
transaction BNKL Stock Option (right to buy) Options Exercise $0 -5,000 -100% $0.000000* 0 15 Jul 2021 Common Stock, par value $0.001 per share 5,000 $3.16 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Payment of exercise price was satisfied through the satisfaction of an Issuer promissory note held by the Reporting Person.
F2 The options vested 1,666 on May 31, 2019, 1,666 on November 30, 2019 and 1,668 on May 31, 2020.